UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 14,727	$ 18,555	$ 8,505
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	700	765	660
Amortization	6,144	2,191	2,113
Gain on Investments	0	(32)	0
Provision for losses on accounts receivable	14	20	4
Amortization of Right of Use Assets	38	0	0
Loss/(Gain) on disposal of assets	16	(410)	17
Deferred income taxes	(396)	(326)	(658)
Stock-based compensation expense	113	64	129
Tax benefit attributable to exercise of stock options	23	49	0
Accounts receivable	(738)	(496)	(242)
Other receivables	(16)	0	2
Inventories	(1,686)	(244)	(467)
Prepaid expenses and other current assets	(16)	(68)	24
Accounts payable	114	52	9
Accrued expenses	(1,651)	(558)	1,027
Long-term repatriation tax payable	(330)	(2,728)	5,785
Net cash provided by operating activities	17,056	16,834	16,908
CASH FLOWS FROM INVESTING ACTIVITIES:
Property and equipment	(540)	(402)	(1,597)
Intangible assets	(21,000)	0	0
Proceeds from the sale of investments	0	74	0
Proceeds from the sale of property and equipment	0	862	0
Net cash provided by (used in) investing activities	(21,540)	534	(1,597)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock - options	283	454	302
Common stock purchased and retired	(398)	(1,205)	0
Tax benefit attributable to exercise of stock options	0	0	0
Dividends paid	(4,112)	(4,026)	(2,955)
Net cash (used in) financing activities	(4,227)	(4,777)	(2,653)
Effect of exchange rate changes on cash	386	(1,354)	921
Net increase in cash and cash equivalents	(8,325)	11,237	13,579
Cash at beginning of year	51,112	39,875	26,296
Cash at end of year	42,787	51,112	39,875
Cash paid during the period for income taxes	5,304	4,851	5,151
Cash paid during the period for interest	$ 0	$ 0	$ 0